Company Description
ImmunityBio, Inc., a clinical-stage biotechnology company, engages in developing therapies and vaccines that bolster the natural immune system to defeat cancers and infectious diseases.
Its platforms for the development of biologic product candidates include antibody-cytokine fusion proteins; DNA, RNA, and recombinant protein vaccines; and cell therapies.
The company's platforms have generated therapeutic agents that are currently being or planned to be studied in clinical trials across various indications in liquid and solid tumors, including bladder, lung and colorectal cancers, and glioblastoma multiforme.
Its lead biologic product candidate is Anktiva, an FDA-approved immunotherapy in combination with bacillus calmette-guérin (BCG) for the treatment of adult patients with BCG unresponsive non-muscle invasive bladder cancer with carcinoma in situ, with or without papillary tumors.
The company has collaboration agreements with National Cancer Institute. It also has license agreements with 3M Innovative Properties Company; Access to Advanced Health Institute; LadRx Corporation; Sanford Health; Shenzhen Beike Biotechnology Co. Ltd.; Viracta Therapeutics, Inc.; and GlobeImmune, Inc. The company is based in San Diego, California.
Country | United States |
Founded | 2014 |
Industry | Biotechnology |
Sector | Healthcare |
Employees | 628 |
CEO | Richard Gerald Adcock |
Contact Details
Address: 3530 John Hopkins Court San Diego, California 92121 United States | |
Phone | (844) 696-5235 |
Website | immunitybio.com |
Stock Details
Ticker Symbol | IBRX |
Exchange | NASDAQ |
Fiscal Year | January - December |
Reporting Currency | USD |
CIK Code | 0001326110 |
CUSIP Number | 45256X103 |
ISIN Number | US45256X1037 |
Employer ID | 43-1979754 |
SIC Code | 2836 |
Key Executives
Name | Position |
---|---|
Dr. Patrick Soon-Shiong F.A.C.S., FRCS (C), M.Sc. | Executive Chairman of the Board, Global Chief Scientific and Medical Officer |
Richard Gerald Adcock | President, Chief Executive Officer and Director |
David C. Sachs | Chief Financial Officer, Principal Financial Officer and Principal Accounting Officer |
Dr. Barry J. Simon M.D. | Chief Corporate Affairs Officer and Director |
Dr. Leonard S. Sender M.D. | Chief Operating Officer |
Dr. Enrique Diloné Ph.D., RAC | Chief Technology Officer |
Jason R. Liljestrom | General Counsel and Corporate Secretary |
Sarah Singleton | Chief Communications Officer and Head of Patient Advocacy |
Dr. Sandeep K. Reddy M.D. | Chief Medical Officer |
Dr. Hans Georg Klingemann M.D., Ph.D. | Chief Science Officer of Cellular |
Latest SEC Filings
Date | Type | Title |
---|---|---|
May 9, 2024 | 10-Q | Quarterly Report |
May 2, 2024 | EFFECT | Notice of Effectiveness |
Apr 29, 2024 | DEFA14A | Additional definitive proxy soliciting materials and Rule 14(a)(12) material |
Apr 29, 2024 | DEF 14A | Other definitive proxy statements |
Apr 29, 2024 | ARS | Filing |
Apr 23, 2024 | 8-K | Current Report |
Apr 17, 2024 | S-3ASR | Automatic shelf registration statement of securities of well-known seasoned issuers |
Mar 29, 2024 | S-3 | Registration statement under Securities Act of 1933 |
Mar 19, 2024 | 10-K | Annual Report |
Feb 26, 2024 | 8-K | Current Report |